Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06744205 · ClinicalTrials.gov registry record · Phase 1
A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older
A Phase 1 study of Healthy Volunteers and Influenza, sponsored by Sanofi Pasteur, a Sanofi Company.
- Active
- Registry status
- Phase 1
- Development phase
- 1,162
- Enrollment target
- 20
- Study locations
NCT06744205 is a Phase 1 study of Healthy Volunteers and Influenza that is active but no longer recruiting, run by Sanofi Pasteur, a Sanofi Company. The registered enrollment target is 1,162 participants, above the 478-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (143% higher). The trial reports 20 study locations across 13 states.
The verdict
NCT06744205, a Phase 1 study of Healthy Volunteers and Influenza, is active but no longer recruiting, sponsored by Sanofi Pasteur, a Sanofi Company.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 1,162 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TIV mRNA-neuraminidase (NA) compared to an active control ((Fluzone standard-dose quadrivalent influenza vaccine (QIV-SD) or Fluzone high-dose quadrivalent influenza vaccine (QIV-HD) in adults 50 years of age and older.
Conditions Studied
Interventions
- BIOLOGICAL Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1
- BIOLOGICAL TIV mRNA-neuraminidase (NA)
- BIOLOGICAL TIV mRNA-HA Vaccine 2
- BIOLOGICAL Quadrivalent Influenza Standard Dose Vaccine
- BIOLOGICAL Quadrivalent Influenza Vaccine High Dose
Study Locations (20)
Florida
- AMR Miami- Site Number : 8400021 - Coral Gables
- Accel Research Sites Network - DeLand Clinical Research Unit- Site Number : 8400003 - DeLand
- Alliance for Multispeciality Research - Fort Myers- Site Number : 8400013 - Fort Myers
- Accel Research Sites - Maitland- Site Number : 8400007 - Maitland
- Innovation Medical Research Center - Palmetto Bay- Site Number : 8400011 - Palmetto Bay
Alabama
- Accel Research Sites Network - Birmingham- Site Number : 8400008 - Birmingham
- AMR Mobile- Site Number : 8400022 - Mobile
Kansas
- Alliance for Multispeciality Research - Newton- Site Number : 8400020 - Newton
- Alliance for Multispeciality Research - Wichita East- Site Number : 8400014 - Wichita
Massachusetts
- Boston Clinical Trials- Site Number : 8400009 - Boston
- ActivMed Practices & Research- Site Number : 8400005 - Methuen
Arizona
- Alliance for Multispeciality Research - Clinical Research Consortium- Site Number : 8400015 - Tempe
Georgia
- Accel Research Site - NeuroStudies.net, LLC - ERN - PPDS- Site Number : 8400001 - Decatur
Illinois
- AMR - Chicago- Site Number : 8400012 - Oak Brook
Kentucky
- Alliance for Multispeciality Research - Lexington- Site Number : 8400018 - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,162 participants |
| Start Date | 2025-01-06 |
| Est. Completion | 2026-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06744205
The ClinicalTrials.gov registry entry for NCT06744205 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 1,162 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 478-participant average among 283 other Healthy Volunteers trials with a reported enrollment target (143% higher). The listed sponsor is Sanofi Pasteur, a Sanofi Company, which has 153 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Healthy Volunteers appearing as the primary indexed condition, and to 5 interventions - of which Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 is the first listed.
NCT06744205 reports 20 study locations spanning 13 distinct geographic areas - top geographies include Florida, Alabama, Kansas.
Frequently Asked Questions
What is clinical trial NCT06744205 about?
NCT06744205 is a clinical study titled "A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older". The purpose of this study is to evaluate the safety and immunogenicity of a single intramuscular injection of different formulations of a hexavalent influenza messenger ribonucleic acid (mRNA) vaccine composed of differing dose levels of trivalent (TIV) mRNA hemagglutinin (HA) in combination with TI...
What is the current status of trial NCT06744205?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 1,162 participants. The study started on 2025-01-06. Estimated completion is 2026-04-16.
What conditions does trial NCT06744205 study?
This clinical trial studies the following conditions: Healthy Volunteers, Influenza.
What interventions are being tested in trial NCT06744205?
The interventions under investigation include: Trivalent (TIV) messenger ribonucleic acid (mRNA) hemagglutinin (HA) Vaccine 1 (BIOLOGICAL), TIV mRNA-neuraminidase (NA) (BIOLOGICAL), TIV mRNA-HA Vaccine 2 (BIOLOGICAL), Quadrivalent Influenza Standard Dose Vaccine (BIOLOGICAL), Quadrivalent Influenza Vaccine High Dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT06744205?
This trial is sponsored by Sanofi Pasteur, a Sanofi Company, which has 153 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06744205 being conducted?
This trial has 20 study locations across Alabama, Arizona, Florida, Georgia, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Research Study to Evaluate the Safety of NNC4004-0002 When Given to Participants With Asymptomatic Hyperuricemia
RECRUITING · Phase 1
-
A Phase 1 Study to Evaluate the Safety and Pharmacokinetics of ABBV-243 in Healthy Adults.
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of ABBV-277 in Healthy Adult Participants
RECRUITING · Phase 1
-
A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.
RECRUITING · Phase 1
-
Classroom Break, Cognition, and Fitness in Elementary School Children
RECRUITING · Phase 1
-
A Study to Assess the Relative Bioavailability of BMS-986435 and Food Effect on the BMS-986435 in Healthy Adult Participants
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.